Recent News

• 06.13.2025 - Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
• 06.13.2025 - Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
• 06.13.2025 - Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
• 06.13.2025 - Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
• 06.13.2025 - Tiziana Life Sciences to Present at the Bio International Convention
• 06.13.2025 - Tiziana Life Sciences to Present at the Bio International Convention
• 06.13.2025 - Tiziana Life Sciences to Present at the Bio International Convention
• 06.13.2025 - Tiziana Life Sciences to Present at the Bio International Convention
• 05.23.2025 - Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
• 05.23.2025 - Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

Recent Filings

• 06.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.13.2025 - EX-99.1 EX-99.1
• 06.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.13.2025 - EX-99.1 EX-99.1
• 06.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.23.2025 - EX-99.1 EX-99.1
• 05.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]